Repatha is not a statin. It belongs to a completely different class of cholesterol-lowering medications called PCSK9 inhibitors, which work through a distinct biological mechanism and are taken as injections rather than daily pills. The two drug types are often used together, but they are not interchangeable.
How Repatha Works
Repatha (evolocumab) is a monoclonal antibody, meaning it’s a lab-engineered protein designed to target one specific molecule in your body. In this case, it targets a protein called PCSK9 that your liver naturally produces. Under normal circumstances, PCSK9 floats through your bloodstream and latches onto LDL receptors on liver cells, essentially marking them for destruction. Fewer LDL receptors means your liver pulls less “bad” cholesterol out of your blood.
Repatha blocks PCSK9 from reaching those receptors. With PCSK9 out of the way, more LDL receptors survive on the surface of liver cells, and your liver clears LDL cholesterol from your bloodstream more efficiently. In clinical trials, this mechanism reduced LDL cholesterol by roughly 60%, with some studies showing reductions between 50% and 81% depending on the dose and patient population.
How Statins Work Differently
Statins lower cholesterol by a fundamentally different route. They block an enzyme inside liver cells that’s responsible for the very first step of cholesterol production. By shutting down this enzyme, statins reduce the amount of cholesterol your liver manufactures. The liver compensates by producing more LDL receptors on its surface to pull cholesterol from the blood, which is actually the same endpoint Repatha achieves, just from the opposite direction.
Statins are oral medications taken as a daily pill. Common examples include atorvastatin and rosuvastatin. Repatha, by contrast, is a subcutaneous injection given either every two weeks (140 mg) or once a month (420 mg), typically into the abdomen, thigh, or upper arm.
Why People Take Both Together
Repatha is frequently prescribed alongside a statin rather than as a replacement. Because the two drugs lower cholesterol through separate pathways, combining them produces a larger reduction in LDL than either one alone. In the LAPLACE-2 trial, patients already on statin therapy who added Repatha saw additional LDL reductions of 59% to 66% on top of what the statin was already doing.
The FDA has approved Repatha for several overlapping situations: reducing the risk of heart attack, stroke, and other major cardiovascular events in adults at elevated risk; lowering LDL in adults with high cholesterol; and treating inherited forms of very high cholesterol (familial hypercholesterolemia) in adults and children aged 10 and older. In most of these scenarios, a statin is the first-line treatment, and Repatha is added when LDL levels remain too high despite statin therapy.
Side Effects Compared to Statins
One of the main reasons people search for alternatives to statins is muscle pain. Statins are linked to elevated levels of a muscle enzyme called creatine kinase and can cause soreness, weakness, or cramping in some patients. A large network meta-analysis found that statins were also associated with a small increase in new-onset diabetes and liver enzyme elevation, neither of which was seen with PCSK9 inhibitors.
Repatha’s most notable side effect is related to its delivery method. Because it’s an injection, some people develop redness, swelling, or discomfort at the injection site. Beyond that, its overall safety profile in clinical trials has been comparable to placebo for most common side effects.
Cardiovascular Benefits
The strongest evidence for Repatha’s heart-protective effects comes from the FOURIER trial, which enrolled over 27,500 patients with established cardiovascular disease who were already taking statins. After an average follow-up of 2.2 years, adding Repatha reduced the combined risk of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, and coronary procedures by 15%. A secondary measure that focused specifically on heart attacks, strokes, and cardiovascular death showed a 20% relative risk reduction.
These results are on top of whatever benefit the statin was already providing, which reinforces the point that the two medications complement each other rather than compete.
Who Might Get Repatha Instead of a Statin
For people who genuinely cannot tolerate any statin due to muscle symptoms or other side effects, Repatha can serve as a standalone cholesterol-lowering option. It’s also used alone or with other non-statin therapies in patients with familial hypercholesterolemia whose cholesterol is dangerously high regardless of diet and exercise. But for the majority of patients, Repatha is an add-on therapy, not a statin substitute, because statins remain effective, well-studied, inexpensive, and convenient as a daily pill.